Drug Trial Radar · NCT03925857
Prevention of Sepsis-related Organ Dysfunction With Allocetra-OTS
Last checked: Nov 19, 2026Latest source record: May 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jan 27, 2019
Primary completion
Dec 10, 2019
Study completion Jan 12, 2020
Sponsor
- Lead sponsor
- Enlivex Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial evaluates the safety and efficacy of one and two doses of the study drug, Allocetra-OTS, in patients who have been diagnosed with sepsis.
Conditions
- Organ Dysfunction Syndrome Sepsis
Interventions
Allocetra-OTSBiological
Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of safety by determining the number of participants with any Adverse Events (AE),Serious Adverse Events (SAE) and fatal SAETime frame: 28 days follow up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hadassah Medical Center
Jerusalem, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.